Company Overview of Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. develops and manufactures branded and generic pharmaceutical products for healthcare professionals and patients in India and the United States. It offers generic pharmaceutical products in the areas of oral and injectable cephalosporins; cardiovascular; controlled release ANDA's; and paragraph IV's. It also offers fermentation products; Suprax, an anti-infective product available in tablets and suspension formulations in pediatric and other physician practices for children; cephalosporin API’s; ACE-inhibitors and cholesterol reducing agents; and Amabelz (Estradiol and Norethindrone Acetate tablets) for treatment of moderate to severe vasomotor symptoms due to meno...
111 South Calvert Street
Baltimore, MD 21202
Founded in 2003
Key Executives for Lupin Pharmaceuticals, Inc.
Chief Executive Officer and Managing Director
Compensation as of Fiscal Year 2016.
Lupin Pharmaceuticals, Inc. Key Developments
Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. Partially Settle Class Action Lawsuit Involving the Antibiotic Drug Solodyn
Apr 28 17
Partial settlements have been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (Defendants) violated state competition (antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective. To settle the lawsuit, Lupin Pharmaceuticals Inc. and Lupin Limited (Lupin Defendants) and Sandoz Inc. have each agreed: that they would be willing to provide certain witnesses that Plaintiffs could call and a declaration that the Plaintiffs could use during the Solodyn case involving the overall End-Payor Class, other Plaintiffs, and the Non-Settling Defendants; and to deposit $625,000 and $1.75 million, respectively, into Settlement Funds. If the Settlements are approved by the Court and become final, the Settlement Funds, inclusive of interest, will be used to: pay for costs and expenses incurred or to be incurred by Counsel in continuing the lawsuit against Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., and Impax Laboratories, Inc. (Non-Settling Defendants); cover taxable costs and taxes payable on the Settlement Funds; pay for notice and other expenses; and pay for service awards not to exceed $10,000 to the class representatives in recognition of their efforts to date on behalf of the Classes. Any remainder in the Settlement Funds, after the payment of the above expenses, shall be distributed to the End-Payor Class for the Lupin Settlement and the End-Payor Class for the Sandoz Settlement in a manner approved by the court at the conclusion of the litigation. These settlements involve only the Lupin Defendants and Sandoz. The case will continue against the non-settling defendants.
Vanda Pharmaceuticals Inc. Files Separate Patent Infringement Lawsuits against Roxane Laboratories, Inc., Inventia Healthcare Pvt. Ltd., Lupin Ltd. and Lupin Pharmaceuticals, Inc
Dec 19 16
Vanda Pharmaceuticals Inc. (company) has filed separate patent infringement lawsuits in the United States District Court for the District of Delaware against Roxane Laboratories, Inc., Inventia Healthcare Pvt. Ltd. (Inventia), and Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin) (collectively, the Defendants) seeking an adjudication that the respective Defendants infringed one or more claims of the Company's U.S. Patent No. 9,138,432 (the 432 Patent) and/or the company's U.S. Patent No. 8,586,610 (the 610 Patent) by submitting to the U.S. Food and Drug Administration an Abbreviated New Drug Application for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025 or the 610 Patent in November 2027, as applicable. A trial on these matters was scheduled to begin on May 15, 2017. On December 15, 2016, following a submission by the parties suggesting that it may be appropriate to remove the May 15, 2017 trial from the District Court's calendar pending the Federal Circuit decision in Roxane's appeal of the District Court's August 25, 2016 ruling finding that Roxane's proposed products infringed the asserted claims of the 610 Patent (as previously disclosed), the District Court removed the May 15, 2017 trial from the calendar and adopted a new schedule for discovery. Additionally, within fourteen days after any decision on the merits in the Roxane appeal, the parties will submit to the District Court a status report and request a schedule for trial. Vanda and Inventia have entered into a confidential stipulation regarding any potential launch date of Inventia's generic ANDA product. Vanda and Lupin have also entered into a confidential stipulation regarding any potential launch date of Lupin's ANDA Product.
Lupin Pharmaceuticals, Inc. Receives FDA Approval for Generic Topicort Ointment
Dec 6 16
Lupin Limited announced that its US subsidiary, Lupin Pharmaceuticals, Inc. has received final approval for its Desoximetasone Ointment USP, 0.25% from the United States Food & Drug Administration (FDA) to market a generic version of Taro Pharmaceuticals, Inc.'s Topicort® Ointment, 0.25%. Lupin's Desoximetasone Ointment USP, 0.25% is the AB rated generic equivalent of Taro Pharmaceuticals, Inc.'s Topicort® Ointment, 0.25%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|